Prognostic and diagnostic significance of preoperative Jumonji domain‑containing 6 antibodies in colorectal cancer

Yoshida,Kimihiko; Hiwasa,Takaki; Ito,Masaaki; Ushigome,Mitsunori; Takizawa,Hirotaka; Li,Shu-Yang; Zhang,Bo-Shi; Iwadate,Yasuo; Funahashi,Kimihiko; Shimada,Hideaki

doi:10.3892/ol.2023.13713

Prognostic and diagnostic significance of preoperative Jumonji domain‑containing 6 antibodies in colorectal cancer

Authors:
- Kimihiko Yoshida
- Takaki Hiwasa
- Masaaki Ito
- Mitsunori Ushigome
- Hirotaka Takizawa
- Shu-Yang Li
- Bo-Shi Zhang
- Yasuo Iwadate
- Kimihiko Funahashi
- Hideaki Shimada
View Affiliations

Affiliations: Department of Surgery, School of Medicine, Toho University, Tokyo 143‑8541, Japan, Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo 143‑8541, Japan, Port Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba 260‑0025, Japan, Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan
Published online on: February 10, 2023 https://doi.org/10.3892/ol.2023.13713
Article Number: 127

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Jumonji domain‑containing 6 (JMJD6) protein has been reported to be upregulated in different cancer cells; however, to the best of our knowledge, no report has analyzed serum anti‑JMJD6 antibodies (s‑JMJD6‑Abs) in patients with cancer. Therefore, the present study evaluated the clinical significance of s‑JMJD6‑Abs in patients with colorectal cancer. Preoperative serum samples were analyzed from 167 patients with colorectal cancer who underwent radical surgery between April 2007 and May 2012. The pathological stages were as follows Stage I (n=47), stage II (n=56), stage III (n=49) and stage IV (n=15). In addition, 96 healthy participants were analyzed as controls. s‑JMJD6‑Abs were analyzed by amplified luminescent proximity homology assay‑linked immunosorbent assay. The cutoff value of s‑JMJD6‑Abs for detecting colorectal cancer was calculated to be 5,720 using the receiver operating characteristic curve. The positive rate of s‑JMJD6‑Abs was 37% in patients with colorectal cancer (61 of 167), independent of carcinoembryonic antigen or carbohydrate antigen 19‑9 and p53‑Abs. Clinicopathological factors and prognosis were compared between the s‑JMJD6‑Abs‑positive group and the s‑JMJD6‑Abs‑negative group. The s‑JMJD6‑Ab‑positive status was significantly associated with older age (P=0.03), but was not associated with other clinicopathological variables. Regarding recurrence‑free survival, the s‑JMJD6‑positive status was a significant poor prognostic factor in both univariate (P=0.02) and multivariate (P<0.01) analyses. Similarly, regarding overall survival, the s‑JMJD6‑Abs‑positive status was a significant poor prognostic factor in both univariate (P=0.03) and multivariate (P=0.01) analyses. In conclusion, preoperative s‑JMJD6‑Abs was positive in 37% of patients with colorectal cancer and may be considered an independent poor prognostic biomarker.

View Figures

View References

1	Yang J, Chen S, Yang Y, Ma X, Shao B, Yang S, Wei Y and Wei X: Jumonji domain-containing protein 6 protein and its role in cancer. Cell Prolif. 53:e127472020. View Article : Google Scholar : PubMed/NCBI
2	Poulard C, Rambaud J, Lavergne E, Jacquemetton J, Renoir JM, Tredan O, Chabaud S, Treilleux I, Corbo L and Le Romancer M: Role of JMJD6 in breast tumourigenesis. PLoS One. 10:e01261812015. View Article : Google Scholar : PubMed/NCBI
3	Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET and Desai KV: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res. 14:R852012. View Article : Google Scholar : PubMed/NCBI
4	Liu X, Si W, Liu X, He L, Ren J, Yang Z, Yang J, Li W, Liu S, Pei F, et al: JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component. Mol Cancer. 16:1752017. View Article : Google Scholar : PubMed/NCBI
5	Lee CR, Lee SH, Rigas NK, Kim RH, Kang MK, Park NH and Shin KH: Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties. Carcinogenesis. 37:119–128. 2016. View Article : Google Scholar : PubMed/NCBI
6	Zhang J, Ni SS, Zhao WL, Dong XC and Wang JL: High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma. Tumour Biol. 34:2397–2401. 2013. View Article : Google Scholar : PubMed/NCBI
7	Wan J, Liu H, Yang L, Ma L, Liu J and Ming L: JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4. Int J Cancer. 144:2489–2500. 2019. View Article : Google Scholar : PubMed/NCBI
8	Zheng H, Tie Y, Fang Z, Wu X, Yi T, Huang S, Liang X, Qian Y, Wang Xi, Pi R, et al: Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer. Signal Transduct Target Ther. 4:242019. View Article : Google Scholar : PubMed/NCBI
9	Wang F, He L, Huangyang P, Liang J, Si W, Yan R, Han X, Liu S, Gui B, Li W, et al: JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation. PLoS Biol. 12:e10018192014. View Article : Google Scholar : PubMed/NCBI
10	Miller TE, Liau BB, Wallace LC, Morton AR, Xie Q, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q, et al: Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature. 547:355–359. 2017. View Article : Google Scholar : PubMed/NCBI
11	Zhou DX, Zhou D, Zhan SQ, Wang P, Qin K, Gan W and Lin XF: Inhibition of JMJD6 expression reduces the proliferation, migration and invasion of neuroglioma stem cells. Neoplasma. 64:700–708. 2017. View Article : Google Scholar : PubMed/NCBI
12	Aprelikova O, Chen K, El Touny LH, Brignatz-Guittard C, Han J, Qiu T, Yang HH, Lee MP, Zhu M and Green JE: The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis. Clin Epigenetics. 8:382016. View Article : Google Scholar : PubMed/NCBI
13	Zaneker P, Gray ES and Ziman MR: Autoantibody production in cancer-the humoral immune response toword autologous antigens in cancer patients. Autoimmun Rev. 15:477–483. 2016. View Article : Google Scholar : PubMed/NCBI
14	Ushigome M, Shimada H, Miura Y, Yoshida K, Kaneko T, Koda T, Nagashima Y, Suzuki T, Kagami S and Funahashi K: Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: Serum p53 antibodies, CA19-9 and CEA. Int J Clin Oncol. 25:622–632. 2020. View Article : Google Scholar : PubMed/NCBI
15	Sumazaki M, Shimada H, Ito M, Shiratori F, Kobayashi E, Yoshida Y, Adachi A, Matsutani T, Iwadate Y, Mine S, et al: Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Sci. 111:4453–4464. 2020. View Article : Google Scholar : PubMed/NCBI
16	Hiwasa T, Wang H, Goto K, Mine S, Machida T, Kobayashi E, Yoshida Y, Adachi A, Matsutani T, Sata M, et al: Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Med. 19:1312021. View Article : Google Scholar : PubMed/NCBI
17	Li SY, Yoshida Y, Kobayashi E, Kubota M, Matsutani T, Mine S, Machida T, Maezawa Y, Takemoto M, Yokote K, et al: Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis. Sci Rep. 11:134502021. View Article : Google Scholar : PubMed/NCBI
18	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
19	Maes T, Carceller E, Salas J, Ortega A and Buesa C: Advances in the development of histone lysine demethylase inhibitors. Curr Opin Pharmacol. 23:52–60. 2015. View Article : Google Scholar : PubMed/NCBI
20	Ran T, Xiao R, Huang Q, Yuan H, Lu T and Liu W: In silico discovery of JMJD6 inhibitors for cancer treatment. ACS Med Chem Lett. 10:1609–1613. 2019. View Article : Google Scholar : PubMed/NCBI
21	Ushigome M, Shimada H, Nabeya Y, Shiratori F, Soda H, Takiguchi N, Hoshino I, Kuwajima A, Kaneko T and Funahashi K: Possible predictive significance of serum RalA autoantibodies on relapse-free survival in patients with colorectal cancer. Mol Clin Oncol. 14:182021. View Article : Google Scholar : PubMed/NCBI
22	Ushigome M, Nabeya Y, Soda H, Takiguchi N, Kuwajima A, Tagawa M, Matsushita K, Koike J, Funahashi K and Shimada H: Multi-panel assay of serum autoantibodies in colorectal cancer. Int J Clin Oncol. 23:917–923. 2018. View Article : Google Scholar : PubMed/NCBI
23	Takashi S, Satoshi Y, Akihiko O, Naoya Y, Yusuke T, Kentaro M, Yu O, Yasuaki N, Koichi Y, Takashi F, et al: Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma: A multi-institutional study. Esophagus. 18:65–71. 2021. View Article : Google Scholar : PubMed/NCBI